These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17982903)

  • 1. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.
    Miüller N; Schwarz MJ
    J Neural Transm Suppl; 2007; (72):269-80. PubMed ID: 17982903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
    Muller N; Schwarz M
    Neurotox Res; 2006 Oct; 10(2):131-48. PubMed ID: 17062375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunology in schizophrenic disorders].
    Müller N; Schwarz MJ
    Nervenarzt; 2007 Mar; 78(3):253-6, 258-60, 262-3. PubMed ID: 16897051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological treatment options for schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1606-13. PubMed ID: 22283758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
    Müller N; Myint AM; Schwarz MJ
    Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 inhibition in schizophrenia and major depression.
    Müller N; Schwarz MJ
    Curr Pharm Des; 2008; 14(14):1452-65. PubMed ID: 18537668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
    Myint AM; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in schizophrenia.
    Müller N; Myint AM; Schwarz MJ
    Adv Protein Chem Struct Biol; 2012; 88():49-68. PubMed ID: 22814706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
    Müller N
    Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory treatment in schizophrenia.
    Müller N; Myint AM; Krause D; Weidinger E; Schwarz MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():146-53. PubMed ID: 23178230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
    Müller N
    Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
    Müller N; Schwarz MJ
    Mol Psychiatry; 2007 Nov; 12(11):988-1000. PubMed ID: 17457312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.
    Müller N; Schwarz MJ
    Eur Arch Psychiatry Clin Neurosci; 2008 Jun; 258 Suppl 2():97-106. PubMed ID: 18516521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.
    Almulla AF; Vasupanrajit A; Tunvirachaisakul C; Al-Hakeim HK; Solmi M; Verkerk R; Maes M
    Mol Psychiatry; 2022 Sep; 27(9):3679-3691. PubMed ID: 35422466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.
    da Silva Araújo T; Maia Chaves Filho AJ; Monte AS; Isabelle de Góis Queiroz A; Cordeiro RC; de Jesus Souza Machado M; de Freitas Lima R; Freitas de Lucena D; Maes M; Macêdo D
    J Psychiatr Res; 2017 Jan; 84():49-58. PubMed ID: 27697587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunological treatment options for schizophrenia].
    Müller N; Krause D; Weidinger E; Schwarz M
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):210-9. PubMed ID: 24710677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.
    Thomas SR; Stocker R
    Redox Rep; 1999; 4(5):199-220. PubMed ID: 10731095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.
    Schwieler L; Larsson MK; Skogh E; Kegel ME; Orhan F; Abdelmoaty S; Finn A; Bhat M; Samuelsson M; Lundberg K; Dahl ML; Sellgren C; Schuppe-Koistinen I; Svensson C; Erhardt S; Engberg G
    J Psychiatry Neurosci; 2015 Mar; 40(2):126-33. PubMed ID: 25455350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.
    Wichers MC; Maes M
    J Psychiatry Neurosci; 2004 Jan; 29(1):11-7. PubMed ID: 14719046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.